Dysarthria in Parkinson's Disease: Lusophony vs. Francophony Comparison

NCT ID: NCT02753192

Last Updated: 2016-04-27

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 120 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-01-31
• Study Completion Date: 2017-07-31

Brief Summary

Parkinson's disease (PD) affects between 1% and 2% of the world's population aged 60 and older; in Europe the prevalence is around 150 PD patients per 100,000 individuals. PD is classically characterized by a symptomatic triad that includes rest tremor, akinesia and hypertonia and although the motor expression of the symptoms involves mainly the limbs, the muscles implicated in speech production are also subject to specific dysfunctions. Motor speech disorders, so-called dysarthria, can thus be developed by PD patients. The main objective of our project is to evaluate the physiological parameters (acoustics), perceptual markers (intelligibility) and psychosocial impact of dysarthric speech in PD, in the context of language (French vs. Portuguese) modulations. Acoustic parameters are expected to be physiologically-based, linked with the motoric aspects of dysarthric speech. The same degree of impairment of such parameters should be associated with the pathology and be present universally in all patients, even if they speak different languages; that should be also the case of prosodic markers, whereas impairment of speech intelligibility may participate to the psychosocial impact in communication alteration.

PD patients will be enrolled in the study in Aix-en-Provence (N = 60) and Lisbon (N = 60). Their global motor disability will be assessed with dedicated clinical rating scales, without (off) and with (on) pharmacological treatment. Two groups of 60 healthy age-matched volunteers will provide the normal reference for between-group comparisons. Along with the off and on medication clinical examinations, several speech tasks will be recorded. Moreover, speech organ functions will also be assessed during the same examination. The psychosocial impact of dysarthria will be evaluated via self-questionnaires; it will be analysed a posteriori, as well as the speech intelligibility evaluation, and both will strengthen the overall speech assessments. This global investigation will represent a unique opportunity to provide the most precise and reliable description of PD patients' speech and its impacts on intelligibility and quality of life. Challenging and interdisciplinary aspects are combined in our project, which original cross-linguistic approach involves an international collaboration definitely new in the field of motor speech disorders.

Detailed Description

Background - Individuals with Parkinson's disease (PD) have to deal with several aspects that contribute to voice and speech decline and thus, alteration of communication ability during the course of the disease: (i) The orofacial motor dysfunction, so-called dysarthria, which depends on the neurodegenerative processes; (ii) The effects of the medical treatment, which vary according to the disease stage; and (iii) The particular speech modifications that can be language-specific, i.e. dependent on the language spoken by the patients. The main objective of the FralusoPark project is to evaluate changes in dysarthric speech in PD as a result of medical treatment and disease duration using acoustic parameters (voice and prosody), perceptual markers (intelligibility), and patient-based outcomes (the psychosocial impact on quality of life) in two different languages (French vs. European Portuguese).

Methods - Individuals with PD will be enrolled in the study in Aix-en-Provence, France (N = 60) and Lisbon, Portugal (N = 60). Their global motor disability and orofacial motor functions will be assessed with specific clinical rating scales, without (OFF) and with (ON) medical treatment. Two groups of 60 healthy age-matched volunteers will provide the reference for between-group comparisons. Along with the clinical examinations, several speech tasks will be recorded to obtain acoustic and perceptual measures. Self-evaluation questionnaires will be used to assess the psychosocial impact of dysarthria on quality of life.

Discussion - Our three a priori hypotheses are the following: (i) Global acoustic features are altered similarly in French and Portuguese individuals with PD; (ii) Language-specific prosodic patterns might be altered differently according to the language spoken by the patients; and (iii) The impact of speech disorders on intelligibility and quality of life depends on the cultural and linguistic environment. The study combines an interdisciplinary and cross-linguistic approach to study motor speech disorders and will allow for a better understanding of the progression of speech symptoms in PD and their response to medical treatment. It will provide recommendations on how to assess speech and voice disorders in individuals with PD in order to monitor symptom progression and management.

Conditions

Parkinson's Disease; Dysarthria; Speech; Cross-language; Medical Treatment; Disease Progression

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Blinding Strategy: NONE

Study Groups

Patients

Individuals with PD will be enrolled in the study in Aix-en-Provence, France (N = 60) and Lisbon, Portugal (N = 60). Their global motor disability and orofacial motor functions will be assessed with specific clinical rating scales, without (OFF) and with (ON) medical treatment. Two groups of 60 healthy age-matched volunteers will provide the reference for between-group comparisons.

Group Type: OTHER

Patients

Intervention Type: OTHER

Individuals with PD will be enrolled in the study in Aix-en-Provence, France (N = 60) and Lisbon, Portugal (N = 60). Their global motor disability and orofacial motor functions will be assessed with specific clinical rating scales, without (OFF) and with (ON) medical treatment. Two groups of 60 healthy age-matched volunteers will provide the reference for between-group comparisons. Along with the clinical examinations, several speech tasks will be recorded to obtain acoustic and perceptual measures. Self-evaluation questionnaires will be used to assess the psychosocial impact of dysarthria on quality of life.

Interventions

Patients

Individuals with PD will be enrolled in the study in Aix-en-Provence, France (N = 60) and Lisbon, Portugal (N = 60). Their global motor disability and orofacial motor functions will be assessed with specific clinical rating scales, without (OFF) and with (ON) medical treatment. Two groups of 60 healthy age-matched volunteers will provide the reference for between-group comparisons. Along with the clinical examinations, several speech tasks will be recorded to obtain acoustic and perceptual measures. Self-evaluation questionnaires will be used to assess the psychosocial impact of dysarthria on quality of life.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

All participants

• Age between 35 and 85 years old
• Good cooperation
• Ability to understand the information sheet
• Given signed consent
• Affiliation to a medical-social insurance regimen
• Other stable medical problems not interfering with the proposed study

Only for patients:

• Absence of any neurological, psychiatric or behavioral pathology
• Idiopathic Parkinson's disease
• Absence of medication-induced psychosis, severe depression or dementia

Exclusion Criteria

All participants

• Illiteracy
• French/Portuguese not as native language, or bilingual participants
• Participant under tutorship or guardianship, or any other administrative or legal measure
• No cooperation or withdrawn consent
• Cognitive deficits, depression, psychosis or behavioral, neurological, medical, psychological disorders that may interfere with vital prognostic and evaluations

Only for patients:

• Non-idiopathic Parkinson's disease
• (Too) severe motor impairment impeding to participate in the study

• Minimum Eligible Age: 35 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Instituto de Medicina Molecular João Lobo Antunes

OTHER

Sponsor Role: collaborator

Centre National de la Recherche Scientifique, France

OTHER

Sponsor Role: lead

Responsible Party

Serge Pinto

Dr. Serge Pinto, Ph.D.

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Serge Pinto, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

Laboratoire Parole et Langage, Aix-en-Provence, France

Joaquim J Ferreira, M.D, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

Instituto de Medicina Molecular, Lisobon School of Medicine, Lisbon, Portugal

Locations

Centre Hospitalier du Pays d'Aix - Service de Neurologie

Aix-en-Provence, , France

Site Status: RECRUITING

Santa Maria University Hospital

Lisbon, , Portugal

Site Status: RECRUITING

Campu Neurologico Senior (CNS)

Torres Vedras, , Portugal

Site Status: RECRUITING

Countries

France; Portugal

Central Contacts

Serge Pinto, Ph.D.

Role: CONTACT

serge.pinto@lpl-aix.fr

(33)650568713

Facility Contacts

François Viallet, M.D., Ph.D.

Role: primary

fviallet@ch-aix.fr

Serge Pinto, Ph.D.

Role: backup

serge.pinto@lpl-aix.fr

(33)6 50568713

Rita Cardoso, M.Sc

Role: primary

ritasicardoso@gmail.com

Joaquim J Ferreira, M.D, Ph.D.

Role: backup

joaquimjferreira@gmail.com

Rita Cardoso, M.Sc

Role: primary

ritasicardoso@gmail.com

Joaquim J Ferreira, M.D., Ph.D.

Role: backup

joaquimjferreira@gmail.com

References

Pinto S, Cardoso R, Sadat J, Guimaraes I, Mercier C, Santos H, Atkinson-Clement C, Carvalho J, Welby P, Oliveira P, D'Imperio M, Frota S, Letanneux A, Vigario M, Cruz M, Martins IP, Viallet F, Ferreira JJ. Dysarthria in individuals with Parkinson's disease: a protocol for a binational, cross-sectional, case-controlled study in French and European Portuguese (FraLusoPark). BMJ Open. 2016 Nov 17;6(11):e012885. doi: 10.1136/bmjopen-2016-012885.

Reference Type: DERIVED

PMID: 27856480 (View on PubMed)

Other Identifiers

ANR-13-ISH2-0001-01

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

FCT-ANR/NEU-SCC/0005/2013

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

13017

Identifier Type: -

Identifier Source: org_study_id